PDIC-DPC

PDIC-DPC (2 mg/kg; i.v.; every 3 days) significantly reduces ESCC lung metastasis, enhances CD³⁺, CD⁸⁺, and GzmB⁺ T cell infiltration in metastatic foci, and prolongs survival in C57BL/6 mice^[1].
PDIC-DPC (2 mg/kg; i.v.; every 3 days) significantly reduces lung metastasis of HMGA1-overexpressing ESCC, enhances CD3⁺, CD8⁺, and GzmB⁺ T cell infiltration in metastatic foci, and prolongs survival in C57BL/6 mice^[1].
PDIC-DPC (2 mg/kg; i.v.; every 10 days; 4 months) reduces orthotopic ESCC burden, suppresses HMGA1 expression, and enhances T lymphocyte infiltration in 4NQO-induced ESCC models in both wild-type and HMGA1 knock-in mice^[1].
PDIC-DPC (every two days; 14 days) achieves superior reversal of bleomycin-induced pulmonary fibrosis in C57BL/6N mice, as evidenced by a 1.4 Ashcroft score, 96% pulmonary function recovery relative to normal mice, and 100% survival rate, via activation of AMPK and suppression of the TGFβ-Smad pathway^[2].
PDIC-DPC (20 mg/kg; daily; 28 days) exhibits highly selective lung accumulation in healthy C57BL/6N mice, with excellent in vivo biocompatibility at doses up to 20 mg/kg over 28 days^[2].